Synapse - Steven Horwitz

Search Within

Steven M Horwitz

Results (671)

Tub-010, a novel antibody-drug-conjugate with reduced nonspecific toxicity profile based on tub-tag technology widens the therapeutic window for the treatment of CD30+malignancies

Meeting Abstract

Gerlach, M.; Schmitt, S.; Cyprys, P.; Kasper, M. A.; Mai, I.; Vermeer, M. H.; Horwitz, S. M.; Fingerle-Rowson, G. R.; Vogl, A.; Schumacher, D.; more...
Blood (2022)

Fulltext@MSK | Save

Duvelisib in patients with relapsed/refractory peripheral T-cell lymphoma from the phase 2 primo trial expansion phase: Impact of prior treatment and expanded safety analysis

Meeting Abstract

Jacobsen, E. D.; Zinzani, P. L.; Zain, J.; Mead, M.; Casulo, C.; Gritti, G.; Pinter-Brown, L. C.; Izutsu, K.; Daugherty, M.; Brammer, J. E.; more...
Blood (2022)

Fulltext@MSK | Save

Characterization of a large cohort of patients with nodal marginal zone lymphoma shows prolonged survival, time-to-treatment, and time-to-transformation

Meeting Abstract

Stuver, R.; Drill, E.; Qualls, D.; Okwali, M.; Batlevi, C. L.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; more...
Blood (2022)

Fulltext@MSK | Save

Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing

Meeting Abstract

Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
Blood (2022)

Fulltext@MSK | Save

Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma

Meeting Abstract

Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
Blood (2022)

Fulltext@MSK | Save

Primary cutaneous peripheral T-cell lymphoma, not otherwise specified: Characterization of a large cohort with long-term outcomes shows disparate outcomes by body region involvement

Meeting Abstract

Stuver, R.; Ghione, P.; Ganesan, N.; Noor, S.; Imber, B. S.; Pulitzer, M.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Identifying primary refractory disease and early relapses in peripheral T-cell lymphoma using baseline characteristics, minimal residual disease, and mutational profiling

Meeting Abstract

Stuver, R.; Haynie, H.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Mazloom, A.; Moskowitz, A. J.; Drill, E.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Outcomes for patients with relapsed and refractory peripheral T-cell lymphoma in the 21st century by relapse status, salvage therapy, and receipt of allogeneic transplant

Meeting Abstract

Stuver, R.; Epstein-Peterson, Z. D.; Johnson, W. T.; Khan, N.; Sauter, C. S.; Scordo, M.; Shah, G. L.; Moskowitz, A. J.; Horwitz, S. M.
Blood (2022)

Fulltext@MSK | Save

Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience

Meeting Abstract

Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
Blood (2022)

Fulltext@MSK | Save

Brentuximab vedotin combined with chemotherapy in newly diagnosed, early-stage, unfavorable-risk Hodgkin lymphoma: Extended follow-up with evaluation of baseline metabolic tumor volume and PET2

Meeting Abstract

Stuver, R.; Michaud, L.; Casulo, C.; Advani, R. H.; Budde, E. L.; Barr, P. M.; Batlevi, C. L.; Caron, P. C.; Constine, L. S.; Dandapani, S.; more...
Blood (2022)

Fulltext@MSK | Save